BTIG Research Cuts GeneDx (NASDAQ:WGS) Price Target to $90.00

Key Points

• BTIG cut its price target for GeneDx from $170 to $90 while keeping a "buy" rating, implying about a 32.5% upside from the prior close and sitting below the street consensus price target of $120.83.
• GeneDx missed Q1 estimates with a GAAP loss of ($0.28) vs. a ($0.06) consensus and revenue of $102.25M (below ~$112–114M est.), and management issued FY revenue guidance of $475–$490M versus the street's ~ $549M, heightening near‑term margin and cash‑flow concerns.
• Management reported strong underlying demand—34% year‑over‑year volume growth in exome/genome testing—yet the quarter showed operating/net losses; insiders have both sold shares recently (including a small CFO sale) and a director made a large purchase, with insiders owning ~29.6% of the stock.

GeneDx (NASDAQ:WGS - Get Free Report) had its price objective decreased by stock analysts at BTIG Research from $170.00 to $90.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. BTIG Research's price target would suggest a potential upside of 32.49% from the company's previous close.

WGS has been the topic of several other reports. Canaccord Genuity Group set a $100.00 price target on GeneDx and gave the stock a "buy" rating in a report on Monday, April 20th. Wells Fargo & Company restated an "overweight" rating on shares of GeneDx in a report on Tuesday. Zacks Research cut GeneDx from a "strong-buy" rating to a "hold" rating in a report on Friday, April 24th. Guggenheim reduced their price target on GeneDx from $170.00 to $100.00 and set a "buy" rating on the stock in a report on Monday, March 30th. Finally, Piper Sandler restated an "overweight" rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $120.83.

GeneDx Stock Performance

NASDAQ:WGS opened at $67.93 on Tuesday. The stock has a market cap of $1.99 billion, a P/E ratio of -90.57 and a beta of 2.06. The company has a current ratio of 2.46, a quick ratio of 2.34 and a debt-to-equity ratio of 0.16. The stock's 50-day moving average is $71.45 and its 200-day moving average is $107.17. GeneDx has a 1-year low of $55.17 and a 1-year high of $170.87.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The firm had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.During the same quarter last year, the firm posted ($0.23) earnings per share. Equities research analysts anticipate that GeneDx will post 0.75 earnings per share for the current year.

Insider Buying and Selling

In other GeneDx news, CFO Kevin Feeley sold 392 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total transaction of $25,554.48. Following the transaction, the chief financial officer directly owned 34,942 shares in the company, valued at approximately $2,277,868.98. This represents a 1.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Keith A. Meister purchased 140,026 shares of the business's stock in a transaction on Thursday, March 5th. The shares were acquired at an average price of $81.19 per share, for a total transaction of $11,368,710.94. Following the completion of the acquisition, the director directly owned 3,228,150 shares in the company, valued at approximately $262,093,498.50. This represents a 4.53% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have sold 109,989 shares of company stock valued at $7,888,023. Insiders own 29.60% of the company's stock.

Hedge Funds Weigh In On GeneDx

Institutional investors and hedge funds have recently modified their holdings of the business. Kestra Advisory Services LLC bought a new position in shares of GeneDx during the 4th quarter worth approximately $27,000. Jones Financial Companies Lllp boosted its holdings in shares of GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock worth $25,000 after buying an additional 186 shares in the last quarter. Ramirez Asset Management Inc. bought a new position in shares of GeneDx during the 4th quarter worth approximately $33,000. Greenline Wealth Management LLC bought a new position in shares of GeneDx during the 4th quarter worth approximately $33,000. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of GeneDx during the 4th quarter worth approximately $35,000. 61.72% of the stock is currently owned by institutional investors.

Key Stories Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Strong underlying volume growth: management reported 34% year‑over‑year volume growth in exome and genome testing, supporting longer‑term demand for the core business. GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
• Neutral Sentiment: Revenue and gross profit were higher year‑over‑year ($102.3M revenue; gross profit up ≈17%), indicating growth despite near‑term margin pressure. GeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 Earnings
• Neutral Sentiment: Conference call materials and transcript are available for more detail on drivers and cadence of margin recovery; listeners can assess management commentary for guidance color. GeneDx Holdings Corp. (WGS) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 EPS missed materially: GAAP loss per share of ($0.28) vs. consensus loss of ($0.06), with revenue below estimates (~$102.25M vs. ~$112–114M est.), a primary catalyst for downward pressure. GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Lags Revenue Estimates
• Negative Sentiment: Full‑year revenue guidance markedly below consensus: management set FY revenue of roughly $475–$490M vs. street ~$549M, increasing downside risk to near‑term estimates and valuation. GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
• Negative Sentiment: Profitability and cash flow stress: the quarter showed a large operating and net loss and meaningful operating cash outflow, which raises execution and financing concerns until margins and cash generation improve. GeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 Earnings
• Negative Sentiment: Insider selling: recent disclosure shows the CFO sold shares (~$25.6k reported) and several insiders have sold shares in recent months, which markets often view as a negative signal. Insider Selling: GeneDx NASDAQ: WGS CFO Sells $25,554.48 in Stock

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.